Sequential topoisomerase I (topo I) and topoisomerase II (topo II) inhibitors in relapsed/refractory aggressive NHL: Results of CALGB 59906, a phase II study of doxorubicin and topotecan.

被引：0
|
作者：
Smith, SM
Johnson, JL
Niedzwiecki, D
Eder, JP
Canellos, GP
Cheson, BD
Bartlett, NL
机构：
[1] Univ Chicago, Dept Med, Chicago, IL 60637 USA
[2] Duke Univ, Canc & Leukemia Grp B, Ctr Stat, Durham, NC USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA
[5] Washington Univ, St Louis, MO USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.2500.2500
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2500
引用
收藏
页码：685A / 686A
页数：2
相关论文
共 50 条
  • [1] A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide
    Hammond, LA
    Eckardt, JR
    Ganapathi, R
    Burris, HA
    Rodriguez, GA
    Eckhardt, SG
    Rothenberg, ML
    Weiss, GR
    Kuhn, JG
    Hodges, S
    Von Hoff, DD
    Rowinsky, EK
    CLINICAL CANCER RESEARCH, 1998, 4 (06) : 1459 - 1467
  • [2] TOPOISOMERASE-I (TOPO-I) AND TOPOISOMERASE-II (TOPO-II) LEVELS IN HIGH AND LOW-GRADE LYMPHOMAS
    POTMESIL, M
    HSIANG, YH
    LIU, LF
    KNOWLES, D
    KIRSCHENBAUM, S
    TRAGANOS, F
    SILBER, R
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 176 - 176
  • [3] Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: Results of CALGB 59906
    Smith, Sonali M.
    Johnson, Jeffrey L.
    Niedzwiecki, Donna
    Eder, J. Paul
    Canellos, George
    Cheson, Bruce D.
    Bartlett, Nancy L.
    LEUKEMIA & LYMPHOMA, 2006, 47 (08) : 1511 - 1517
  • [4] LEVELS OF DNA TOPOISOMERASE-I (TOPO-I) AND TOPOISOMERASE-II (TOPO-II) IN HUMAN COLORECTAL-CARCINOMA AND NORMAL COLONIC MUCOSA
    HSIANG, YH
    LIU, LF
    HOCHSTER, H
    POTMESIL, M
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 172 - 172
  • [5] Is cytoplasmic localization of topoisomerase I (topo I) a mechanism of resistance for topo I inhibitors? Results from an NCCN sponsored phase II trial of gemcitabine and irinotecan in metastatic breast cancer.
    Moulder, Stacy L.
    Valkov, Nikola
    Gump, Jana
    Munster, Pamela
    Minton, Susan
    Horton, John
    Lacevic, Mensura
    Lima, Caio Rocha
    Sullivan, Dan
    CANCER RESEARCH, 2006, 66 (08)
  • [6] A single arm phase II trial of gemcitabine (G) and irinotecan (I) in metastatic breast cancer: Can localization of topoisomerase I (topo I) predict response to topo I inhibitors?
    Moulder, S. L.
    Valkov, N.
    Minton, S.
    Munster, P.
    Gump, J.
    Lacevic, M.
    Rocha-Lima, C.
    Horton, J.
    Lush, R.
    Sullivan, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 43S - 43S
  • [7] PHASE-I AND PHARMACOLOGICAL STUDY OF TOPOTECAN (TPT), A-TOPOISOMERASE (TOPO) I-INHIBITOR, IN PATIENTS (PTS) WITH REFRACTORY LEUKEMIAS
    ADJEI, AA
    ROWINSKY, EK
    DONEHOWER, RC
    JONES, RJ
    BURKE, PJ
    GORE, S
    GROCHOW, LB
    KAUFMANN, SH
    BLOOD, 1993, 82 (10) : A443 - A443
  • [8] Sequential topotecan (topoisomerase I inhibitor) and etoposide (topoisomerase II inhibitor) in advanced, adult solid tumours
    Watson, JV
    Bulusu, VR
    Deary, A
    BRITISH JOURNAL OF CANCER, 1998, 78 : 34 - 34
  • [9] MHC class II restriction of autoreactive T cell clones responsive to DNA topoisomerase I (topo I).
    Kuwana, M
    Inoko, H
    Medsger, TA
    Wright, TM
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S202 - S202
  • [10] AGE-RELATED VARIATION IN THE ACTIVITIES OF DNA TOPOISOMERASE (TOPO-I AND TOPO-II) IN MOUSE-LIVER NUCLEI
    SAHAI, BM
    KAPLAN, JG
    FEDERATION PROCEEDINGS, 1985, 44 (03) : 856 - 856
12345